( ence and technology and all other stat...)ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent,Health

ence and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. The Company's actual results could differ materially from expected results as a result of a number of factors, including the fact that preliminary results involved only a small number of test mice, the subsequent investigations were limited in scope, the uncertainties inherent in research and development collaborations, pre- clinical and clinical trials and product development programs, (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials) the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in the Company's periodic report on Form 10-QSB for the three months ended September 30, 2006 and on Form 10-KSB for the twelve months ended December 31, 2005 as filed with the Securities and Exchange Commission. There are no guarantees that any of the Company's proposed products will prove to be commercially successful. The Company undertakes no duty to update forward- looking statements. Contact:

     MEDIA CONTACT:

     W. Jason Grimley

     Spelling Communications

     310-477-9500

     


     INVESTOR CONTACT:

     Josh Reynolds

     CEOcast, Inc.

     212-732-4300

     


     IN-HOUSE INVESTOR CONTACT:
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab
Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP
Therapeutic Data at American Diabetes Association Meeting
4. IR BioSciences Announces Promising Data from Study of Its Compound
Homspera
5. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data
From Nerve Regeneration Program at American Society for Neural
Therapy and Repair Meeting
6. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets
Primary Endpoint in Patients with Post-Surgical Pain
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher
Identifies New Roles in Skin Cancer Prevention for Key Tumor
Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of
Stem Cells Results in Hematopoietic Recovery Following Lethal
Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis